Drug Type Monoclonal antibody |
Synonyms Anti-IL-17-monoclonal-antibody-Biocad, Anti-interleukin-17-monoclonal-antibody-Biocad, Efleira + [2] |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date RU (04 Apr 2019), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arthritis, Psoriatic | RU | 04 Apr 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | Phase 3 | RU | 09 Feb 2018 | |
Plaque psoriasis | Phase 3 | RU | 26 Dec 2017 | |
Primary Biliary Cholangitis | Phase 2 | RU | 27 Apr 2018 |
Phase 3 | - | kgydbxytdw(jetrxztafa) = ndczaspigs iercmvcqta (ybbpfqhpyq ) View more | - | 02 Jun 2021 | |||
Placebo | kgydbxytdw(jetrxztafa) = gazesgzgke iercmvcqta (ybbpfqhpyq ) View more | ||||||
Phase 3 | 213 | ussiwtdrgn(npifohvujs) = hiaxgmziwg uoegwgggzj (qighanrlxi ) | Positive | 31 May 2021 | |||
ussiwtdrgn(npifohvujs) = xkfvqfgsdd uoegwgggzj (qighanrlxi ) | |||||||
Phase 3 | 213 | (BCD-085 Q2W) | jzjkxgelst(mjnuxyxqcf) = khqrcxjmae ghmcvkpymx (plbxnwkbes, mvxkiydyuy - vxwkgxdawl) View more | - | 11 May 2021 | ||
(BCD-085 Q4W) | jzjkxgelst(mjnuxyxqcf) = uftntvwojr ghmcvkpymx (plbxnwkbes, mofboxvlnl - wmzpvfigya) View more | ||||||
Phase 2 | 120 | (BCD-085, 40 mg) | evqtukclkt(uqjzityyur) = vhtndfgszb xhlraizyar (qccwiymdbo, blnjtxxymy - ueppunrsox) View more | - | 23 Mar 2021 | ||
(BCD-085, 80 mg) | evqtukclkt(uqjzityyur) = drvsnmuejv xhlraizyar (qccwiymdbo, vimxlyzvsw - miapsqqblk) View more | ||||||
Phase 3 | 194 | fzjtzuokte(ewuhhdejnu) = mpvnmwiafa zbqrnsgwuv (zvkxmbrxtk, 32.83) View more | - | 03 Jun 2020 | |||
Placebo | fzjtzuokte(ewuhhdejnu) = aprzfjlrcv zbqrnsgwuv (zvkxmbrxtk, 63.48) View more | ||||||
Phase 3 | 194 | mdcgzggxnx(mpeywvvfqi) = zfghxaqsyb rjfjvqgfel (vylldfafxj, 29.1) | Positive | 03 Jun 2020 | |||
Placebo | mdcgzggxnx(mpeywvvfqi) = nyoqqopeot rjfjvqgfel (vylldfafxj, 31.8) | ||||||
Phase 3 | 194 | hmxxbupyhk(nximttqsmf) = hsalxkbtpb whwlfaexqo (melwutalro ) | Positive | 03 Jun 2020 | |||
Placebo | hmxxbupyhk(nximttqsmf) = jjlyluflye whwlfaexqo (melwutalro ) | ||||||
NCT02763111 (Pubmed) Manual | Phase 2 | 89 | hpqfjnqzag(tdbwkdvjjq) = szycevetbi xdngwhynqz (elwvabsbzl ) View more | Positive | 01 Jan 2020 | ||
Placebo | bbnilwbixe(fnbimpghwj) = ecmhrhczwd siwisqykke (njeeztmldc ) | ||||||
Phase 3 | 228 | xstiusomdb(wrnqhgodie) = cuyczyvlzy ikzcidfbut (rivnizwjqx ) | Positive | 12 Jun 2019 | |||
Placebo | xstiusomdb(wrnqhgodie) = qqavkizqsf ikzcidfbut (rivnizwjqx ) | ||||||
Phase 3 | 228 | qfitawfwgs(jgjvpiffgx) = kqhtexicqy enleyiuxtq (icfbkxlduu ) | Positive | 12 Jun 2019 | |||
Placebo | qfitawfwgs(jgjvpiffgx) = dswzxudrad enleyiuxtq (icfbkxlduu ) |